Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Current Size And Growth Outlook For The Liver Diseases Therapeutics Market?
The therapeutics market for liver diseases has seen a robust growth over the past few years. The market value is expected to rise from $14.16 billion in 2024 to $15.18 billion in 2025, with a 7.2% Compound annual growth rate (CAGR). The historic expansion of this market is linked to the high frequency of liver disorders, habits of alcohol consumption, improvements in diagnostic technologies, obesity and metabolic syndrome issues, awareness and screening initiatives, as well as government-led hepatitis control programs.
There is an anticipated strong surge in the liver diseases therapeutics market in the coming years. The market is projected to expand to $22.08 billion in 2029, with a compound annual growth rate (CAGR) of 9.8%. The forecasted growth can be linked to precision medicine methods, breakthroughs in RNA therapeutics, emphasis on fibrosis treatments, patient advocacy and support groups, the progression of vaccines for hepatitis, and regulatory backing for orphan drugs. The predicted trend within this period includes progress in hepatitis C treatment, the rise of innovative therapies for liver fibrosis, incorporation of immunotherapies, the use of telemedicine and remote monitoring, and concentration on nutritional interventions.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp
What Core Drivers Are Expected To Influence The Liver Diseases Therapeutics Market?
The escalating occurrence of liver conditions is anticipated to boost the liver disease therapeutics market’s expansion in the future. The term “liver disease” applies to any ailment that impacts the liver. Liver disease treatments assist in managing these conditions through a variety of therapies. For example, the UK government’s Office for Health Improvement and Disparities stated in April 2024 that as of 2022, the mortality rate owing to liver disease in individuals under the age of 75 in England increased to 21.4 per 100,000 population. Men were found to experience 6,664 premature deaths while women accounted for 3,929. Consequently, the surging incidence of liver diseases is propelling the growth of the liver disease therapeutics market.
Which Segmentation Categories Are Highlighted In The Liver Diseases Therapeutics Market Analysis?
The liver diseases therapeuticsmarket covered in this report is segmented –
1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer
2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids
3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
Subsegments:
1) By Hepatitis: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH); Simple Fatty Liver
3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis; Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma
Which Trends Are Likely To Redefine Growth Paths In The Liver Diseases Therapeutics Market?
The prevalence of strategic partnerships is a rising trend in the liver disease therapeutics market. Dominant firms are participating in partnerships to consolidate their standing in this market. For example, in January 2022, Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company based in the United States, joined forces with Merck & Co, another American company active in the liver disease therapeutics sector. The purpose of their collaboration is to research and develop oligonucleotide treatments for non-alcoholic steatohepatitis.
Who Are The Dominant Players In The Liver Diseases Therapeutics Market Today?
Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Which Regional Markets Are Emerging As Key Hubs For The Liver Diseases Therapeutics Market?
North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp
Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2025, By The Business Research Company
Digital Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report
Antisense And Rnai Therapeutics Global Market Report 2025
Transplant Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
